NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
05/09/2023
Voltar para busca
Dado oficial do USPTO
TMALIN
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
16
Atualização mais recente
05/09/2023
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5
Data de depósito
14/04/2022
Data de registro
05/09/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
05/09/2023
Última transação
05/09/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Fundamento do pedido
Intent to use
Primeiro uso
09/06/2022
Primeiro uso no comércio
09/06/2022
Código do desenho
4
Tipo de titular
99
Localização do titular
Suzhou, Jiangsu, CN
Examinador
JAGANNATHAN, SIDDHARTH
Unidade examinadora
M50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
MediLink Therapeutics(Suzhou)Co.,Ltd.
Representantes
Timothy T. Wang NI, WANG & MASSAND, PLLC
Classificação técnica
Classes Nice
Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Vaccines; Anti-cancer preparations; Biological preparations for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Chemical preparations for pharmaceutical or medical purposesfor treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Cytostatics for pharmaceutical purposes; Diagnostic kits consisting primarily of monoclonal antibodiesbuffersreagents for use in disease testing; Diagnostic preparations for medical purposes for detecting the presence of malignantinflammatory and autoimmune disorders and conditions and tissue trauma in humans; Diagnostic reagents for medicinal use; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; Drug delivery agents in the form of antibody-drug conjugate that facilitate the delivery of pharmaceutical preparations; Intravenous fluids used for rehydrationnutrition and the delivery of pharmaceutical preparations; Medicinal preparations for the treatment of infectious diseases and for use in oncology; Medicinal preparations for anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of viralmetabolicendocrinemusculoskeletalcardiovascularcardiopulmonarygenitourinarysexual dysfunctiononcologicalhepatologicalophthalmicrespiratoryneurologicalgastrointestinalhormonaldermatologicalpsychiatric and immune system related diseases and disorders; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseasesbacteria-based diseases or disordersautoimmune diseases or disorderskidney diseases or disordersdiabetes; Pharmaceutical preparations for the prevention of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparationselixirs for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Pharmaceutical products for the prevention and treatment of cancer; Pharmaceutical products for the treatment of viral and infectious diseasesfor the treatment of cancer; Therapeutic pharmaceutical for the treatment of anemiacancercardiovascular system diseasescentral nervous system diseasesperipheral nervous system diseasescirculatory system diseasesdigestive system diseasesautoimmune diseasesbacteria-based diseases and infectious diseases; Tumor suppressing agents
Publicações
Histórico de despachos e eventos da marca no USPTO.
16 publicações encontradas
R.PR
REGISTERED-PRINCIPAL REGISTER
05/09/2023
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
04/08/2023
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
03/08/2023
SUPC
STATEMENT OF USE PROCESSING COMPLETE
03/08/2023
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
03/08/2023
IUAF
USE AMENDMENT FILED
18/07/2023
EISU
TEAS STATEMENT OF USE RECEIVED
18/07/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
02/05/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/03/2023
PUBO
PUBLISHED FOR OPPOSITION
07/03/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
15/02/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2023
DOCK
ASSIGNED TO EXAMINER
01/02/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/04/2022
NWAP
NEW APPLICATION ENTERED
18/04/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace TMALIN ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.